• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

    12/8/23 8:05:42 AM ET
    $ALGS
    $AULT
    $CDMO
    $CLEU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Technology
    Get the next $ALGS alert in real time by email

    Shares of Hello Group Inc. (NASDAQ:MOMO) jumped in pre-market trading after reporting results for the third quarter.

    The company said net revenues decreased by 5.9% year-over-year to RMB3,042.8 million ($417.1 million) during the third quarter. Non-GAAP diluted net income per ADS rose to RMB3.05 (US$0.42) from RMB2.60 in the year-ago period.

    Hello Group shares rose 8.1% to $7.10 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • MBIA Inc. (NYSE:MBI) shares rose 54.8% to $11.43 in pre-market trading after the company announced it declared an extraordinary cash dividend on MBIA common stock of $8.00 per share.
    • Exicure, Inc. (NASDAQ:XCUR) shares gained 53.4% to $0.6597 in pre-market trading after gaining more than 5% on Thursday.
    • FLJ Group Limited (NASDAQ:FLJ) rose 16.7% to $2.31 in pre-market trading after falling over 56% on Thursday.
    • Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares rose 11.4% to $0.2198 in pre-market trading after falling 4% on Thursday.
    • Ault Alliance, Inc.(NYSE:AULT) gained 11% to $0.1020 in pre-market trading after falling around 10% on Thursday.
    • Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares climbed 10.5% to $0.7184 in pre-market trading after the company announced it presented clinical data at Hep-DART 2023 from its Phase 1 studies in HBV and NASH.
    • Tharimmune, Inc. (NASDAQ:THAR) gained 9.3% to $0.6620 in pre-market trading after falling over 5% on Thursday.
    • SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares surged 8.9% to $1.10 in pre-market trading. SELLAS Life Sciences recently announced positive recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in acute myeloid leukemia.
    • Clean Earth Acquisitions Corp. (NASDAQ:CLIN) shares rose 8.3% to $5.40 in pre-market trading after dipping over 28% on Thursday.

    Losers

    • Cyngn Inc. (NASDAQ:CYN) dipped 29.4% to $0.2823 in pre-market trading. Cyngn shares jumped 64% on Thursday after the company announced the issuance of a new patent, US-11,837,089-B2, for its autonomous vehicle and driving solutions.
    • Golden Heaven Group Holdings Ltd. (NASDAQ:GDHG) shares fell 22% to $1.81 in pre-market trading. Golden Heaven Group shares dipped 89% on Thursday after the company announced that it intends to enter into an operating lease framework agreement with a top-tier Chinese amusement group.
    • Troika Media Group, Inc. (NASDAQ:TRKA) shares fell 21.7% to $0.4210 in pre-market trading. Troika Media Group shares fell around 72% on Thursday after the company announced it filed for Chapter 11.
    • Avid Bioservices, Inc. (NASDAQ:CDMO) shares fell 20.8% to $4.19 in pre-market trading after the company reported weak quarterly results.
    • HashiCorp, Inc. (NASDAQ:HCP) shares fell 20.5% to $19.80 in pre-market trading after the company reported third-quarter financial results.
    • Solid Biosciences Inc. (NASDAQ:SLDB) shares fell 19.5% to $4.63 in pre-market trading after surging 68% on Thursday. The company announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its next-generation Duchenne muscular dystrophy gene therapy candidate known as SGT-003.
    • China Liberal Education Holdings Limited (NASDAQ:CLEU) fell 18.4% to $0.2203 in pre-market trading after jumping over 38% on Thursday.
    • Hempacco Co., Inc. (NASDAQ:HPCO) fell 17.7% to $0.3985 in pre-market trading. Hempacco shares jumped 44% on Thursday after the company announced it entered into an exclusive Master Distribution Agreement with CBDAY Global.
    • Save Foods, Inc. (NASDAQ:SVFD) fell 16.4% to $2.55 in pre-market trading. Save Foods shares surged around 42% on Thursday after the company highlighted it's targeting the US carbon credit market following the acquisition of majority ownership in the newly-formed Nitrousink Ltd.
    • RH (NYSE:RH) fell 9.4% to $255.01 in pre-market. RH posted an unexpected loss for its third quarter, while sales missed estimates.

     

    Now Read This: Lululemon, Johnson Outdoors And 3 Stocks To Watch Heading Into Friday

    Get the next $ALGS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGS
    $AULT
    $CDMO
    $CLEU

    CompanyDatePrice TargetRatingAnalyst
    RH
    $RH
    12/12/2025$165.00Buy → Hold
    Stifel
    RH
    $RH
    12/12/2025$220.00 → $185.00Market Perform
    Telsey Advisory Group
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    RH
    $RH
    10/2/2025Outperform → Mkt Perform
    William Blair
    RH
    $RH
    9/12/2025$220.00Outperform → Market Perform
    Telsey Advisory Group
    Aligos Therapeutics Inc.
    $ALGS
    8/18/2025$50.00Buy
    H.C. Wainwright
    Solid Biosciences Inc.
    $SLDB
    6/26/2025$14.00Buy
    Citigroup
    RH
    $RH
    6/24/2025$179.00Neutral → Sell
    Goldman
    More analyst ratings

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Aneja Nikhil

    3 - Aligos Therapeutics, Inc. (0001799448) (Issuer)

    2/19/26 5:54:15 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    2/19/26 2:27:21 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Cumbo Alexander converted options into 30,031 shares and sold $96,923 worth of shares (16,644 units at $5.82), increasing direct ownership by 6% to 235,405 units (SEC Form 4)

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    2/18/26 9:38:15 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kalin Katherine Bach bought $100,806 worth of shares (63,400 units at $1.59), increasing direct ownership by 155% to 104,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    11/21/25 8:45:10 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Sanam bought $1,450 worth of shares (1,000 units at $1.45), increasing direct ownership by 130% to 1,770 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:34:56 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RH downgraded by Stifel with a new price target

    Stifel downgraded RH from Buy to Hold and set a new price target of $165.00

    12/12/25 8:43:14 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on RH with a new price target

    Telsey Advisory Group reiterated coverage of RH with a rating of Market Perform and set a new price target of $185.00 from $220.00 previously

    12/12/25 8:16:25 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Needham initiated coverage on Solid Biosciences with a new price target

    Needham initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

    12/4/25 8:48:04 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    SEC Filings

    View All

    SEC Form 6-K filed by Golden Heaven Group Holdings Ltd.

    6-K - GOLDEN HEAVEN GROUP HOLDINGS LTD. (0001928340) (Filer)

    2/24/26 4:29:47 PM ET
    $GDHG
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 6-K filed by Golden Heaven Group Holdings Ltd.

    6-K - GOLDEN HEAVEN GROUP HOLDINGS LTD. (0001928340) (Filer)

    2/23/26 4:15:01 PM ET
    $GDHG
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 144 filed by Solid Biosciences Inc.

    144 - Solid Biosciences Inc. (0001707502) (Subject)

    2/18/26 9:35:06 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cyngn Adds Former Lyft Exec, Ran Makavy, to Board

    Mr. Makavy led growth at Lyft and later ran its core platform through the 2019 IPO. He also founded Snaptu, which was acquired by Facebook in 2011.MOUNTAIN VIEW, Calif., Feb. 25, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced the appointment of Ran Makavy to its Board of Directors. He brings senior growth and platform leadership experience from Lyft and Facebook, where he helped scale large technology businesses through high-growth phases. At Lyft, Makavy built the growth team which was responsible for getting more drivers and riders to use Lyft and getting them to use

    2/25/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    RH UNVEILS 2026 INTERIORS SPRING SOURCEBOOK

    RH (NYSE:RH) announced today the release of the 2026 RH Interiors Spring Sourcebook, presenting nearly 600 pages of inspired design by internationally renowned designers, artisans and manufacturers. From monastic minimalism to interstellar illumination, the rhythm of reeding to a study in stone, the comprehensive design resource represents the brand's continued commitment to imagination, innovation and quality. To view the full announcement, please click here. ABOUT RH RH (NYSE:RH) is a global curator of design, taste and style in the luxury lifestyle market. Operating across the United States, Canada, the United Kingdom and Europe, the Company offers collections through its retail ga

    2/23/26 9:05:00 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

    SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado. The pevifoscorvir sodium presentation highlights the Phase 1 monotherapy study of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus (HBV) infection. Additionally, the ALG-097558 presentation showcases data from particip

    2/23/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/15/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/15/21 11:16:15 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Leadership Updates

    Live Leadership Updates

    View All

    Cyngn Adds Former Lyft Exec, Ran Makavy, to Board

    Mr. Makavy led growth at Lyft and later ran its core platform through the 2019 IPO. He also founded Snaptu, which was acquired by Facebook in 2011.MOUNTAIN VIEW, Calif., Feb. 25, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced the appointment of Ran Makavy to its Board of Directors. He brings senior growth and platform leadership experience from Lyft and Facebook, where he helped scale large technology businesses through high-growth phases. At Lyft, Makavy built the growth team which was responsible for getting more drivers and riders to use Lyft and getting them to use

    2/25/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

    SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 7:59:25 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Financials

    Live finance-specific insights

    View All

    MBIA Inc. Investor Conference Call to Discuss Full Year and Fourth Quarter 2025 Financial Results Scheduled for Friday, February 27 at 8:00 A.M. Eastern Time

    MBIA Inc. (NYSE:MBI) will host a webcast and conference call for investors on Friday, February 27 at 8:00 a.m. (ET) to discuss its full year and fourth quarter 2025 financial results and other issues related to the Company. The dial-in number for the call is 800-445-7795 in the U.S. and 785-424-1699 from outside the U.S. The conference call code is MBIAQ425. A live webcast of the conference call will also be accessible on www.mbia.com. The conference call will consist of brief comments on the full year and fourth quarter 2025 results followed by a question-and-answer session for investors. MBIA's financial results report and 10-K filing will become available after the market closes on Thu

    2/20/26 11:15:00 AM ET
    $MBI
    Property-Casualty Insurers
    Finance

    Hello Group to Report Fourth Quarter and Fiscal Year 2025 Results on March 18, 2026

    BEIJING, Feb. 13, 2026 /PRNewswire/ -- Hello Group Inc. (NASDAQ:MOMO) (the "Company"), a leading player in Asia's online social networking space, today announced that it will release its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025 before U.S. markets open on Wednesday, March 18, 2026. Hello Group's management will host an earnings conference call on Wednesday, March 18, 2026, at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing / Hong Kong Time on the same day). Preregistration Information Participants can register for the conference call by navigating to https://s1.c-conf.com/diamondpass/10053257-1s7egv.html. Upon registration, each participant w

    2/13/26 6:00:00 AM ET
    $MOMO
    Computer Software: Prepackaged Software
    Technology

    KBW Announces Index Rebalancing for Fourth-Quarter 2025

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE:SF), announces the upcoming index rebalancing for the fourth quarter of 2025. This quarter, there are constituent changes within six of our indexes: KBW Nasdaq Insurance Index (Index Ticker: KIX), KBW Nasdaq Regional Banking Index (Index Ticker: KRX, ETF Ticker: KBWR), KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDX, ETF Ticker: KBWD), KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX, ETF Ticker: KBWY), KBW Nasdaq Property and Casualty Ins

    12/12/25 8:30:00 PM ET
    $AAT
    $ACIW
    $AJG
    Real Estate Investment Trusts
    Real Estate
    Computer Software: Prepackaged Software
    Technology